Last reviewed · How we verify
Methylaminolevulinate PDT in 2 sessions — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Methylaminolevulinate PDT in 2 sessions (Methylaminolevulinate PDT in 2 sessions) — Maastricht University Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Methylaminolevulinate PDT in 2 sessions TARGET | Methylaminolevulinate PDT in 2 sessions | Maastricht University Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Methylaminolevulinate PDT in 2 sessions CI watch — RSS
- Methylaminolevulinate PDT in 2 sessions CI watch — Atom
- Methylaminolevulinate PDT in 2 sessions CI watch — JSON
- Methylaminolevulinate PDT in 2 sessions alone — RSS
Cite this brief
Drug Landscape (2026). Methylaminolevulinate PDT in 2 sessions — Competitive Intelligence Brief. https://druglandscape.com/ci/methylaminolevulinate-pdt-in-2-sessions. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab